These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 802132)

  • 1. [Treatment of obesity with the anoretic Sanorex].
    Tashev T; Ekimova S
    Probl Khig; 1976; 2():189-95. PubMed ID: 802132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical trial with a nonamphetaminic anoretic].
    Campagnoli M
    Rev Iber Endocrinol; 1976; 23(137):463-83. PubMed ID: 794978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mazindol, an anorectic of a new series, in the treatment of obesity (author's transl)].
    Dolecek R
    Cas Lek Cesk; 1975 Feb; 114(8):249-54. PubMed ID: 1095197
    [No Abstract]   [Full Text] [Related]  

  • 4. Controlled clinical evaluation of a new anorectic agent in obese adults.
    Elmaleh MK; Miller J
    Pa Med; 1974 Sep; 77(9):46-50. PubMed ID: 4609056
    [No Abstract]   [Full Text] [Related]  

  • 5. A double blind controlled trial of a new anorectic agent AN448.
    Woodhouse SP; Nye ER; Anderson K; Rawlings J
    N Z Med J; 1975 Jun; 81(542):546-9. PubMed ID: 1099491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
    Geyer G; Haidinger G; Francesconi M; Langmayr N; Prager R; Schoberberger R; Toplak H; von Kalckreuth G; Kunze M
    Acta Med Austriaca; 1995; 22(5):95-101; 104-9. PubMed ID: 8651045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychoactive drug use among overweight psychiatric patients: problem aspect of anorectic drugs.
    Angle HV; Carroll JA; Ellinwood EH
    Chem Depend; 1980; 4(1-2):47-55. PubMed ID: 6927577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic trial of an anorectic agent using the double blind cross-over technic].
    Bienert HR; Uberla K
    Arzneimittelforschung; 1967 Mar; 17(3):336-42. PubMed ID: 4869817
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [L-thyroxine propylhexedrine in the treatment of obesity. Crossed double blind study].
    González Barranco J; Rull JA; Lozano Castañeda O
    Prensa Med Mex; 1974; 39(5-6):298-9. PubMed ID: 4612507
    [No Abstract]   [Full Text] [Related]  

  • 13. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group].
    Héraïef E
    Rev Med Suisse Romande; 1997 Jan; 117(1):19-24. PubMed ID: 9082531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug treatment of obesity].
    Héraïef E; Burckhardt P
    Ther Umsch; 1989 May; 46(5):309-18. PubMed ID: 2662470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alternating low calory diets (200 to 1000 calories), their value in the treatment of resistant obesity].
    Mirouze J; Mary P; Schmouker Y; Lapinski H; Chauchard C; Prunac N
    Sem Hop; 1976 Nov; 52(40):2255-61. PubMed ID: 188176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical trial of drugs (7): trial of an appetite-reducing preparation (Aminorex)].
    Roos BE; Steen B; Svanborg A
    Lakartidningen; 1970 Jun; 67():Suppl II:96+. PubMed ID: 4920753
    [No Abstract]   [Full Text] [Related]  

  • 18. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study.
    Truant AP; Olon LP; Cobb S
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):726-38. PubMed ID: 4629111
    [No Abstract]   [Full Text] [Related]  

  • 19. [Patients with type III obesity given sibutramine 15 mg/day lose weight in amounts proportional to those in types I and II, but waist circumferences does not decrease proportionally].
    López-Alvarenga JC; Vargas JA; Schneider-Ehrenberg OP; Comuzzie AG; González J; Martínez JL
    Gac Med Mex; 2007; 143(2):109-14. PubMed ID: 17585697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options.
    Fujioka K
    Obes Res; 2002 Dec; 10 Suppl 2():116S-123S. PubMed ID: 12490660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.